Literature DB >> 18724243

Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.

Daisuke Nonaka1, Luis Chiriboga, Robert A Soslow.   

Abstract

The ovary is a common site of involvement for metastasis and the breast is one of the most common sources. Metastatic breast carcinoma can mimic a primary ovarian carcinoma. Pax8 is a crucial transcription factor for organogenesis of the thyroid gland, kidney, and Müllerian system, and it also regulates Wilms tumor suppressor gene (WT1) expression. A total of 124 cases of ovarian carcinomas (84 serous papillary, 18 endometrioid, 12 mucinous, 10 clear cell) and 243 cases of invasive breast carcinomas (178 ductal, 65 lobular) were immunostained with Pax8 and WT1 by tissue microarrays to see the differential expression. Pax8 reaction was found in 108 of 124 ovarian carcinomas (87.1%) generally in diffuse staining, including 81 of 84 serous papillary carcinomas (96.4%), 16 of 18 endometrioid carcinomas (88.9%), 10 of 10 clear cell carcinomas (100%), and 1 of 12 mucinous carcinomas (8.3%), whereas WT1 expression was seen in 78 of 124 ovarian carcinomas (62.9%), including 73 of 84 serous papillary carcinomas (86.9%), and 5 of 18 endometrioid carcinomas (27.8%), with no expression in all 10 clear cell carcinomas and 12 mucinous carcinomas. All the mammary carcinomas were completely negative for Pax8, but WT1 expression was seen in 5 of 243 cases (2.1%). Pax8 is a useful marker in the differential diagnosis of ovarian and breast carcinomas, and it seems to be superior to WT1 for the diagnosis of all types of nonmucinous ovarian carcinomas, notably clear cell and endometrioid types where WT1 expression is generally negative or only focal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724243     DOI: 10.1097/PAS.0b013e31816d71ad

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  63 in total

1.  An Unlikely Route: Metastatic Ovarian Malignancy within the Duodenum.

Authors:  Sindhura Kolli; Simcha Weissman; Saad Saleem; Owen T M Chan; Maria Ver; Richard Inae; Mel A Ona
Journal:  Gastrointest Tumors       Date:  2019-09-04

2.  Metastatic ovarian papillary serous carcinoma to the breast: Diagnosis and pitfalls.

Authors:  Paulette Mhawech-Fauceglia; Brian Kay; Carrie J Li; Yvonne G Lin
Journal:  Gynecol Oncol Case Rep       Date:  2013-01-04

Review 3.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

4.  Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.

Authors:  Jennifer J Mueller; Brooke A Schlappe; Rahul Kumar; Narciso Olvera; Fanny Dao; Nadeem Abu-Rustum; Carol Aghajanian; Deborah DeLair; Yaser R Hussein; Robert A Soslow; Douglas A Levine; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2018-05-22       Impact factor: 5.482

Review 5.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

6.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

7.  Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma.

Authors:  Tamara L Lotan; Huihui Ye; Jonathan Melamed; Xue-Ru Wu; Ie-Ming Shih; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

8.  A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.

Authors:  Jean-Philippe Meyniel; Paul H Cottu; Charles Decraene; Marc-Henri Stern; Jérôme Couturier; Ingrid Lebigot; André Nicolas; Nina Weber; Virginie Fourchotte; Séverine Alran; Audrey Rapinat; David Gentien; Sergio Roman-Roman; Laurent Mignot; Xavier Sastre-Garau
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

9.  PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.

Authors:  Dima Ghannam-Shahbari; Eyal Jacob; Reli Rachel Kakun; Tanya Wasserman; Lina Korsensky; Ofir Sternfeld; Juliana Kagan; Debora Rosa Bublik; Sarit Aviel-Ronen; Keren Levanon; Edmond Sabo; Sarit Larisch; Moshe Oren; Dov Hershkovitz; Ruth Perets
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

10.  Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas.

Authors:  Grazyna Fedorowicz; Steve Guerrero; Thomas D Wu; Zora Modrusan
Journal:  BMC Med Genomics       Date:  2009-05-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.